Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial

We assessed the efficacy and safety of sintilimab [an anti-programmed death (PD-1)] plus bevacizumab biosimilar (IBI305), and hepatic arterial infusion chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC). The patients received sintilimab (200 mg) plus IBI305 (7.5 mg/kg)...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neoplasma 2023-12, Vol.70 (6), p.811-818
Hauptverfasser:	Liu, Dongming, Mu, Han, Liu, Changfu, Zhang, Weihao, Cui, Yunlong, Wu, Qiang, Zhu, Xiaolin, Fang, Feng, Zhang, Wei, Xing, Wenge, Li, Qiang, Song, Tianqiang, Lu, Wei, Li, Huikai
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized Bevacizumab - therapeutic use Biosimilar Pharmaceuticals - therapeutic use Carcinoma, Hepatocellular - drug therapy Humans Hypertension Liver Neoplasms - drug therapy Prospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!